JW Holdings Corporation operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares JW Holdings with three other
companies in this sector in KOREA (SOUTH) :
sales of 176.50 billion Korean Won [US$151.61 million]
of which 95%
(168.76 billion Korean Won [US$144.97 million]
Kyongbo Pharmaceutical Co Ltd
(191.71 billion Korean Won [US$164.68 million]
of which 37%
was General API).
JW Holdings reported sales of 726.42 billion Korean Won (US$624.00 million)
December of 2019.
a very small
increase of 0.1%
versus 2018, when the company's sales were 725.37 billion Korean Won .
Sales at JW Holdings have increased during each of the previous five years
(and since 2014, sales have increased a total of 27%).
Sales of Other Segment saw an increase
that was more than double the company's growth rate: sales were up
48.3% in 2019, from
25.44 billion Korean Won to 37.71 billion Korean Won .
JW Holdings also saw significant increases in sales in
Medical Equipment (up 7.7% to 95.20 billion Korean Won )
Not all segments of JW Holdings experienced an increase in sales in 2019:
sales of Control Business fell 53.1% to 32.12 billion Korean Won .